#Lymphoma @UCLH. Professor UCL. Chair UK T cell lymphoma working group. Past chair UK CNSL study group. views my own. #WiL #lymsm
London, England
- Tweets 3,531
- Following 605
- Followers 3,133
- Likes 9,911
A phase IIa study of the anti-PD-L1 antibody avelumab in relapsed/refractory PTCL: The AVAIL-T trial
onlinelibrary.wiley.com/doi/…
6
21
2,581
Kate Cwynarski retweeted
Very useful data ! Congrats @ABarrettHaem 👏
New paper alert 👀 thank you to @Haematologica for publishing our analysis of ~30,000 UK classic Hodgkin lymphoma patients, with a focus on the ever-interesting older population. NB: anthracycline is key! haematologica.org/article/vi… @DavidJCutter @graham74GC
1
7
2,462
Kate Cwynarski retweeted
It’s nearly September so it’s nearly time for the national lymphoma management course! Do sign up and be educated, informed and hopefully inspired in lymphoma management.
Join our Lymphoma Management course this September! If you're a healthcare professional who has a role in managing patients with lymphoma, then this is the course for you! Hear from experts and advance your knowledge 👉 lymphoma-action.org.uk/event….
@graham74GC @tobyeyre82 #LymSM
ALT 'Lymphoma Management Expert education for professionals' written. Underneath in an orange outline with large quotation marks 'I’ll be teaching on why lymphoma is so interesting and the first-line management of patients with classical Hodgkin lymphoma. Professor Graham Collins' is written.
2
2
7
1,448
Kate Cwynarski retweeted
British Journal of Haematology | Wiley Online Library. @CwynKate onlinelibrary.wiley.com/doi/…
2
5
256
Kate Cwynarski retweeted
Ready to take your next step in clinical research? Applications for CRTH are now open.
The Clinical Research Training in Hematology (CRTH) program is a nine-month training and mentoring experience designed for early-career hematologists who want to grow as clinical researchers.
Successful applicants will be trained and coached by top-tier experts in their field, who will help you develop your knowledge and skills in clinical science through mentoring and training during two multi-day workshops and a session at the EHA Congress.
Learn more about CRTH and apply by September 15, 2026 (15:00 CEST): eha.fyi/CRTH_2027
5
11
2,002
Kate Cwynarski retweeted
EHA CRTH was a gamechanger for me, academically and personally. Watch the whole interview to get my insights and takes.
If you are interested to pursue a career in clinical research contact me directly!
What does it take to turn a research idea into a clinical trial?
In the latest episode of EHA Unplugged, Prof @EliasKarlMai shares his journey from clinical practice to becoming a principal investigator, including the role that EHA's Clinical Research Training in Hematology (CRTH) program played along the way.
If you're an early-career hematologist looking to strengthen your clinical research skills, expand your network, and learn from experienced mentors, CRTH could be your next step. Applications for the 2027 cohort are open until September 15, 2026 ( CEST).
Listen to the episode and discover where a career in clinical research can take you: tr.ee/K2uCZuNpqq
1
6
850
Kate Cwynarski retweeted
What does it take to turn a research idea into a clinical trial?
In the latest episode of EHA Unplugged, Prof @EliasKarlMai shares his journey from clinical practice to becoming a principal investigator, including the role that EHA's Clinical Research Training in Hematology (CRTH) program played along the way.
If you're an early-career hematologist looking to strengthen your clinical research skills, expand your network, and learn from experienced mentors, CRTH could be your next step. Applications for the 2027 cohort are open until September 15, 2026 ( CEST).
Listen to the episode and discover where a career in clinical research can take you: tr.ee/K2uCZuNpqq
1
1
12
1,945
Kate Cwynarski retweeted
A multicentre phase III clinical trial of dual-epigenetic therapy plus CHOP compared with CHOP in previously untreated patients with peripheral T-cell lymphoma
nature.com/articles/s41408-0…
1
2
16
3,298
Kate Cwynarski retweeted
Congratulations to the authors of the ph3 'MATRix'/IELSG43 trial - the largest randomised trial in PCNSL to date - definitively demonstrating the benefit of thiotepa-ASCT over non-myeloablative chemotherapy post MATRix induction, including a OS benefit. thelancet.com/journals/lance…
5
9
1,241
Kate Cwynarski retweeted
📰🚨 Happy to share our latest work on immunodeficiency-associated primary CNS lymphoma (ID-PCNSL), now published @BloodPortfolio ashpublications.org/blood/ar…
This IPCG study includes 308 patients from 23 centers in 7 countries and represents the largest analysis of ID-PCNSL to date
2
2
3
270
Kate Cwynarski retweeted
van Rooij et al: MYD88 ddPCR on CSF cfDNA for non-invasive diagnosis of CNSL:
- 50 pts with confirmed PCNSL/SCNSL
- 203 with non-CNS lymphoma
- In combination with IL10/CXCL13, liquid biopsy had Sn 54% & Sp 100%
- Median corticosteroid to LP time 13 days
tinyurl.com/mr2fa4nk
1
4
8
902
Kate Cwynarski retweeted
🔥 Published today, and just in time for summer conferences, here are your guidelines for presenting badly
34
430
1,635
149,293
Dorothy Hodgkin: A Life Science science.org/doi/10.1126/scie…
1
4
693
Kate Cwynarski retweeted
Great to see the EHA relapsed Hodgkin guidelines in print. Challenging to write these when access to targted therapies is so variable across Europe.
onlinelibrary.wiley.com/doi/…
3
15
62
4,795
Kate Cwynarski retweeted
The National Lymphoma Management is taking bookings for Sept 2026. It's online. It's cheap (£65). It has an excellent faculty. It covers all you need to know about state of the art lymphoma management. Do sign up!
@LymphomaAction @tobyeyre82
lymphoma-action.org.uk/event…
2
10
23
2,637
Kate Cwynarski retweeted
FrontMIND data interesting (Lenz et al)
• tafa-len-RCHOP v RCHOP IPI3-5 LBCL
• 3y PFS ⬆️ 6-7%
• higher in centrally r/v DLBCL
• no signif OS
• more tox: haem & GI
• no COO difference
• tafa weekly for all 6 cycles
Does benefit overcome tox & logistic impact.
#EHA2026
14
32
6,417
Kate Cwynarski retweeted
Townsend - real world bispecific antibody UK data, 3L+ DLBCL
• whole cohort 40% ORR and 24% CMR
• in trial eligible pts, CMR > 40% which is encouraging.
• pt selection crucial - better with lower PS & if receive 2 cycles
• PFS worse if prior benda < 6mo
#EHA2026
1
20
33
2,369
Kate Cwynarski retweeted
Many congratulations to @ABarrettHaem for delivering a fantastic presentation in the final data of the Avenue trial - avelumab prior to a RATHL approach in Hodgkin. #EHA2026
15
36
2,914
Kate Cwynarski retweeted
bbc.co.uk/news/articles/c4gy…
BBC Piece on UCL CAR-T programme for autoimmune diseases! Well done @drclaireroddie @haem
1
4
12
1,952
Kate Cwynarski retweeted
CONGRESS | #EHA2026 | PRESENTATION
Matthew R. Wilson, Beatson West of Scotland Cancer Centre, Glasgow, presents findings from an international retrospective analysis evaluating HD-MTX for CNS relapse prophylaxis in patients with ultra high-risk LBCL receiving curative-intent chemoimmunotherapy (N = 1,923; HD-MTX, n = 872; no HD-MTX, n = 1,051).
HD-MTX did not significantly reduce 3-year CNS relapse vs no HD-MTX in UHR patients (6.6% vs 6.7%; adjusted HR, 0.95). Rates of isolated CNS relapse were also similar with HD-MTX vs no HD-MTX (4.8% vs 6.6%; adjusted HR, 0.81). In propensity score matching (501 pairs), 3-year CNS relapse was 7.4% vs 6.2% (HR, 0.86), and isolated CNS relapse was 5.3% vs 4.5% (HR, 0.83). No benefit was seen in any individual ultra high-risk subgroup. In the matched cohort, 3-year EFS and OS were similar with HD-MTX vs no HD-MTX (73.8% vs 73.7%; p = 0.65 and 82.6% vs 82.7%; p = 0.94).
Follow our live feed for more updates: loom.ly/ilKkUIM
Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.
#lymphoma #lymsm #MedicalCongress @mattwilson2287
7
10
1,011